Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free GALT Stock Alerts

Galectin Therapeutics (GALT) Financials

Galectin Therapeutics logo
$4.06 -0.31 (-7.09%)
As of 07/10/2026 04:00 PM Eastern
Compare
Annual Income Statements for Galectin Therapeutics

Annual Income Statements for Galectin Therapeutics

This table shows Galectin Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -22 -17 -15 -20 -24 -31 -39 -45 -47 -31
Consolidated Net Income / (Loss)		 -20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Net Income / (Loss) Continuing Operations		 -20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Total Pre-Tax Income 		-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Total Operating Income		 -20 -21 -16 -14 -13 -23 -30 -38 -38 -42 -20
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 20 21 16 14 13 23 30 38 38 42 20
Selling, General & Admin Expense		 6.97 6.16 4.53 7.13 5.97 5.47 6.36 6.62 5.94 5.86 5.80
Research & Development Expense		 13 15 12 6.47 7.47 18 24 32 32 37 14
Total Other Income / (Expense), net		 0.05 0.05 0.01 -0.30 0.14 -0.02 -0.35 -0.42 -2.99 -4.61 -11
Interest Expense		 - - 0.01 0.34 0.09 0.09 0.49 1.03 2.79 5.54 7.33
Interest & Investment Income		 0.05 0.05 0.02 0.04 0.23 0.07 0.00 0.05 0.23 0.34 0.13
Other Income / (Expense), net		 - - - - - 0.00 0.14 0.56 -0.43 0.59 -3.55
Preferred Stock Dividends Declared		 1.10 0.91 1.23 1.15 0.26 0.14 0.17 0.10 0.12 0.15 0.14
Basic Earnings per Share		 ($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Weighted Average Basic Shares Outstanding		 24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 58.53M 59.39M 60.16M 62.31M 63.90M
Diluted Earnings per Share		 ($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Weighted Average Diluted Shares Outstanding		 24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 58.53M 59.39M 60.16M 62.31M 63.90M
Weighted Average Basic & Diluted Shares Outstanding		 24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 59.36M 59.44M 61.90M 63.18M 65.83M

Quarterly Income Statements for Galectin Therapeutics

This table shows Galectin Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -10 -11 -12 -11 -12 -9.61 -7.58 -8.22 -5.56 -5.07
Consolidated Net Income / (Loss)		 -10 -10.00 -11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05
Net Income / (Loss) Continuing Operations		 -10 -10.00 -11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05
Total Pre-Tax Income 		-10 -10.00 -11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05
Total Operating Income		 -9.17 -9.56 -9.65 -11 -9.07 -12 -7.90 -4.63 -4.20 -3.37 -4.08
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.17 9.56 9.65 11 9.07 12 7.90 4.63 4.20 3.37 4.08
Selling, General & Admin Expense		 1.43 1.33 1.59 1.48 1.47 1.32 1.41 1.36 1.59 1.43 1.85
Research & Development Expense		 7.73 8.23 8.05 9.81 7.60 11 6.49 3.26 2.61 1.93 2.23
Total Other Income / (Expense), net		 -1.26 -0.44 -1.84 -1.08 -2.15 0.46 -1.73 -2.90 -3.99 -2.14 -0.97
Interest Expense		 0.84 0.85 1.05 1.27 1.49 1.73 1.74 1.83 1.82 1.94 1.99
Interest & Investment Income		 0.06 0.07 0.08 0.08 0.09 0.09 0.04 0.03 0.04 0.03 0.04
Other Income / (Expense), net		 -0.49 0.34 -0.87 0.11 -0.75 2.10 -0.03 -1.10 -2.21 -0.22 0.98
Preferred Stock Dividends Declared		 -0.01 0.06 0.01 0.06 0.02 0.06 -0.03 0.06 0.04 0.06 0.02
Basic Earnings per Share		 ($0.24) ($0.16) ($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08)
Weighted Average Basic Shares Outstanding		 59.70M 60.16M 61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M
Diluted Earnings per Share		 ($0.24) ($0.16) ($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08)
Weighted Average Diluted Shares Outstanding		 59.70M 60.16M 61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M
Weighted Average Basic & Diluted Shares Outstanding		 61.85M 61.90M 62.15M 62.28M 62.76M 63.18M - 64.06M 64.47M 0.00 65.86M

Annual Cash Flow Statements for Galectin Therapeutics

This table details how cash moves in and out of Galectin Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.28 -10 -12 5.20 39 -20 13 -21 7.07 -11 2.60
Net Cash From Operating Activities		 -17 -16 -16 -10 -11 -21 -24 -31 -33 -42 -24
Net Cash From Continuing Operating Activities		 -17 -16 -16 -10 -11 -21 -24 -31 -33 -42 -24
Net Income / (Loss) Continuing Operations		 -20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Consolidated Net Income / (Loss)		 -20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Amortization Expense		 - - - - 0.04 0.04 0.04 0.03 0.03 0.04 0.05
Non-Cash Adjustments To Reconcile Net Income		 3.40 2.48 1.15 4.79 1.77 1.89 2.22 2.72 3.39 2.96 6.30
Changes in Operating Assets and Liabilities, net		 -0.32 2.54 -0.82 -1.11 0.64 0.94 3.96 4.97 4.68 2.28 0.61
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 14 5.93 3.58 15 50 0.26 37 10 40 31 26
Net Cash From Continuing Financing Activities		 14 5.93 3.58 15 50 0.26 37 10 40 31 26
Issuance of Debt		 - - - - - 0.00 30 10 30 30 21
Issuance of Common Equity		 14 5.93 3.58 15 50 0.26 6.81 - - 0.00 3.24
Other Financing Activities, net		 - - - - - - - 0.00 10 1.23 2.24

Quarterly Cash Flow Statements for Galectin Therapeutics

This table details how cash moves in and out of Galectin Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.40 5.30 -2.11 2.04 1.46 -12 -7.69 6.34 -2.25 6.20 -3.61
Net Cash From Operating Activities		 -7.64 -4.70 -12 -8.33 -8.54 -13 -7.69 -6.60 -3.54 -6.04 -3.87
Net Cash From Continuing Operating Activities		 -7.64 -4.70 -12 -8.25 -8.54 -13 -7.69 -6.60 -3.54 -6.04 -3.87
Net Income / (Loss) Continuing Operations		 -10 -10.00 -11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05
Consolidated Net Income / (Loss)		 -10 -10.00 -11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05
Amortization Expense		 0.01 0.01 0.01 - 0.01 0.01 0.01 0.00 - 0.04 0.01
Non-Cash Adjustments To Reconcile Net Income		 1.27 0.35 1.68 0.95 1.56 -1.16 0.84 1.95 2.92 0.60 -0.14
Changes in Operating Assets and Liabilities, net		 1.52 4.93 -2.31 3.15 1.11 0.33 1.09 -1.03 1.73 -1.18 1.31
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 10 10 10 10 10 0.85 0.00 13 1.30 12 0.26
Net Cash From Continuing Financing Activities		 10 10 10 10 10 0.85 0.00 13 1.30 12 0.26
Issuance of Debt		 - 10 10 10 10 - 0.00 11 - 10 0.26

Annual Balance Sheets for Galectin Therapeutics

This table presents Galectin Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 26 16 4.16 9.01 48 30 42 21 28 17 20
Total Current Assets		 26 16 3.82 8.83 48 29 42 21 28 17 19
Cash & Equivalents		 26 15 3.05 8.25 47 27 40 19 26 15 18
Prepaid Expenses		 0.55 0.43 0.77 0.58 0.73 2.32 2.17 1.96 2.05 2.13 1.72
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.01 0.00 0.34 0.17 0.26 0.14 0.01 0.73 0.49 0.24 0.10
Other Noncurrent Operating Assets		 - - 0.34 0.17 0.26 0.14 - 0.73 0.49 0.24 0.10
Total Liabilities & Shareholders' Equity		 26 16 4.16 9.01 48 30 42 21 28 17 20
Total Liabilities		 1.36 3.78 2.97 2.11 2.87 5.41 39 53 88 121 146
Total Current Liabilities		 1.36 3.78 2.97 2.11 2.82 5.40 9.03 13 16 35 8.03
Accounts Payable		 0.45 0.91 0.61 0.30 1.66 1.29 1.81 3.89 6.43 5.66 3.25
Accrued Expenses		 0.85 2.80 2.29 1.51 1.09 4.04 7.16 9.06 9.18 8.20 4.72
Dividends Payable		 0.07 0.07 0.07 0.30 0.07 0.07 0.07 0.06 0.06 0.06 0.06
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.05 0.01 30 40 73 85 138
Long-Term Debt		 - - - - - 0.00 29 9.86 72 85 134
Other Noncurrent Operating Liabilities		 - - - - 0.05 0.01 1.13 31 1.02 0.05 3.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 7.01 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72
Total Equity & Noncontrolling Interests		 18 10 -0.53 5.18 44 22 0.89 -34 -62 -105 -128
Total Preferred & Common Equity		 18 10 -0.53 5.18 44 22 0.89 -34 -62 -105 -128
Preferred Stock		 0.56 7.24 7.24 7.22 0.54 0.53 0.53 0.51 0.50 0.50 0.49
Total Common Equity		 17 3.05 -7.77 -2.04 43 22 0.37 -34 -62 -105 -128
Common Stock		 158 167 173 194 260 262 271 275 292 296 304
Retained Earnings		 -140 -164 -181 -196 -216 -240 -271 -310 -354 -402 -433

Quarterly Balance Sheets for Galectin Therapeutics

This table presents Galectin Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 22 26 28 29 9.53 16 13 16
Total Current Assets		 22 25 27 29 9.29 15 13 16
Cash & Equivalents		 20 24 26 27 7.43 14 12 14
Prepaid Expenses		 1.25 1.91 1.69 1.61 1.85 1.66 1.20 1.58
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.55 0.43 0.37 0.31 0.24 0.18 0.14 0.07
Other Noncurrent Operating Assets		 0.55 0.43 0.37 0.31 0.24 0.18 0.14 0.07
Total Liabilities & Shareholders' Equity		 22 26 28 29 9.53 16 13 16
Total Liabilities		 73 97 110 121 122 133 136 146
Total Current Liabilities		 11 13 15 25 111 11 136 7.31
Accounts Payable		 2.68 3.80 3.70 2.80 6.53 5.87 5.39 3.12
Accrued Expenses		 7.84 8.84 11 12 6.90 4.85 5.04 4.19
Dividends Payable		 0.00 0.00 0.06 0.00 0.00 0.06 0.00 0.00
Total Noncurrent Liabilities		 63 84 95 96 11 122 0.00 139
Long-Term Debt		 30 51 62 73 11 120 - 136
Other Noncurrent Operating Liabilities		 32 33 33 23 0.14 1.54 0.00 2.98
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72
Total Equity & Noncontrolling Interests		 -53 -73 -84 -94 -114 -119 -125 -132
Total Preferred & Common Equity		 -53 -73 -84 -94 -114 -119 -125 -132
Preferred Stock		 0.51 0.50 0.50 0.50 0.50 0.49 0.49 0.48
Total Common Equity		 -53 -73 -84 -95 -114 -119 -126 -132
Common Stock		 291 293 294 295 297 299 301 305
Retained Earnings		 -344 -366 -378 -390 -411 -419 -427 -438

Annual Metrics And Ratios for Galectin Therapeutics

This table displays calculated financial ratios and metrics derived from Galectin Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 23,929,244.00 29,396,619.00 35,638,698.00 41,136,738.00 56,886,059.00 57,077,055.00 59,341,305.00 59,426,005.00 61,848,657.00 62,761,825.00 63,180,491.00
DEI Adjusted Shares Outstanding		 23,929,244.00 29,396,619.00 35,638,698.00 41,136,738.00 56,886,059.00 57,077,055.00 59,341,305.00 59,426,005.00 61,848,657.00 62,761,825.00 63,180,491.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.88 -0.76 -0.49 -0.37 -0.35 -0.41 -0.52 -0.65 -0.72 -0.75 -0.49
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -30.17% -6.98% 24.35% 16.27% 1.46% -74.65% -28.16% -25.88% -1.87% -8.67% 43.60%
EBIT Growth		 -30.13% -6.98% 24.37% 16.28% 1.21% -74.46% -28.14% -25.81% -1.88% -8.68% 43.52%
NOPAT Growth		 -30.13% -6.98% 24.37% 16.28% 1.21% -74.46% -28.73% -27.08% 0.73% -11.45% 52.67%
Net Income Growth		 -26.85% -7.04% 24.26% 14.38% 4.36% -76.51% -30.10% -27.02% -5.91% -14.56% 34.46%
EPS Growth		 -12.82% 13.64% 35.53% 22.45% -2.63% -5.13% -26.83% -25.00% -13.85% -2.70% 36.84%
Operating Cash Flow Growth		 -36.67% 3.38% 3.15% 35.95% -6.57% -89.91% -17.99% -27.76% -6.15% -26.70% 42.84%
Free Cash Flow Firm Growth		 -21.05% 13.33% -2.97% 20.24% 15.73% -77.54% -4.81% 137.84% -977.67% 40.28% 50.33%
Invested Capital Growth		 32.69% -348.56% 45.35% 41.07% -72.25% -58.55% -174.83% -415.49% 65.50% 15.58% 14.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4.97% 0.39% 12.04% -4.71% -19.30% -12.73% 1.79% -9.93% 2.86% -2.71% 22.31%
EBIT Q/Q Growth		 -4.96% 0.39% 12.05% -4.71% -19.61% -12.71% 1.78% -9.91% 2.86% -2.71% 22.19%
NOPAT Q/Q Growth		 -4.96% 0.39% 12.05% -4.71% -19.61% -12.71% 1.33% -9.13% 2.74% -7.25% 31.09%
Net Income Q/Q Growth		 -4.92% 0.37% 11.98% -5.05% -18.62% -13.08% 2.03% -9.65% 1.53% -4.37% 17.34%
EPS Q/Q Growth		 -2.33% 3.80% 15.52% -265.22% 60.61% -17.14% 3.70% -10.17% 2.63% -4.11% 18.64%
Operating Cash Flow Q/Q Growth		 -9.60% -1.64% 5.70% 15.71% -19.26% -8.74% -6.75% -0.94% 7.15% -24.02% 22.04%
Free Cash Flow Firm Q/Q Growth		 -9.75% 0.86% -1.47% 16.03% -5.73% -6.56% -11.91% 125.13% -1,183.79% 1.47% -42.30%
Invested Capital Q/Q Growth		 52.32% 18.66% 58.21% 9.43% -112.75% -184.42% 1.56% -384.56% 65.42% 67.02% 77.69%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.74% 99.79% 99.93% 102.19% 98.93% 100.09% 101.62% 102.60% 106.65% 112.43% 130.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -75.54% -115.67% -245.84% -343.59% -50.65% -67.25% -227.74% 262.19% 88.85% 57.62% 26.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.30% -64.09% 87.78% 416.72% -39.84% -62.90% -189.51% 301.93% 93.14% 59.19% 27.42%
Return on Equity Simple (ROE_SIMPLE)		 -111.01% -208.28% 3,063.21% -268.60% -30.30% -104.43% -3,418.48% 114.33% 66.27% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -15 -11 -9.52 -9.41 -16 -21 -27 -27 -30 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21.78% -31.16% -53.20% -80.05% -14.04% -18.94% -49.98% -124.23% 76.92% 25.26% 16.19%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -272.58% -2,072.79% -241.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -21 -16 -14 -13 -23 -30 -38 -39 -42 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -21 -16 -14 -13 -23 -30 -38 -38 -42 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.24 9.43 0.00 0.00 3.75 5.83 335.62 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.25 9.44 0.00 0.00 3.75 5.83 335.62 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.97 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 11.10 -0.31 -1.19 -1.03 -1.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 11.10 -0.31 -1.19 -0.83 -1.06
Financial Leverage		 -1.03 -1.11 -1.38 -1.35 -1.05 -1.07 -1.40 0.65 -0.41 -0.84 -0.90
Leverage Ratio		 1.06 1.14 1.51 1.63 1.09 1.12 2.66 -2.13 -0.54 -0.28 -0.16
Compound Leverage Factor		 1.06 1.14 1.51 1.66 1.08 1.12 2.71 -2.19 -0.57 -0.31 -0.21
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.74% -44.17% 623.83% 3,365.84% 1,773.67%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 669.11% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.74% -44.17% 623.83% 2,696.74% 1,773.67%
Preferred Equity to Total Capital		 2.22% 60.25% 606.79% 104.65% 1.18% 2.18% 1.66% -2.28% 4.35% 15.84% 6.50%
Noncontrolling Interests to Total Capital		 27.98% 14.34% 144.43% 24.98% 3.78% 7.12% 5.44% -7.72% 14.98% 54.59% 22.85%
Common Equity to Total Capital		 69.80% 25.41% -651.22% -29.63% 95.04% 90.70% 1.16% 154.17% -543.17% -3,336.28% -1,703.02%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -0.26 -1.86 -2.54 -5.67
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.23 -1.20 -2.18 -4.92
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -0.26 -1.86 -2.04 -5.67
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -1.38 -0.37 -2.69 -3.58 -9.51
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.33 -1.73 -3.07 -8.25
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -1.38 -0.37 -2.69 -2.87 -9.51
Altman Z-Score		 8.52 -13.51 -49.53 5.57 27.95 1.20 -8.61 -25.04 -20.89 -40.87 0.00
Noncontrolling Interest Sharing Ratio		 28.12% 44.59% 135.71% 221.28% 21.34% 6.46% 16.79% -15.16% -4.82% -2.72% -1.93%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.41 4.18 1.29 4.19 17.10 5.46 4.63 1.58 1.77 0.49 2.42
Quick Ratio		 19.00 4.06 1.03 3.92 16.84 5.03 4.39 1.43 1.64 0.43 2.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -12 -13 -10 -8.64 -15 -16 6.09 -53 -32 -16
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -1,071.66 -30.53 -99.35 -176.39 -32.89 5.89 -19.13 -5.76 -2.16
Operating Cash Flow to Interest Expense		 0.00 0.00 -1,324.33 -30.29 -124.69 -236.79 -49.71 -30.06 -11.81 -7.54 -3.26
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -1,324.33 -30.29 -124.69 -236.79 -49.71 -30.06 -11.81 -7.54 -3.26
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.73 -3.28 -1.79 -1.06 -1.82 -2.88 -7.93 -41 -14 -12 -10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.36 -2.55 1.49 0.74 -0.76 -1.07 -5.04 -33 27 2.20 1.78
Enterprise Value (EV)		 21 22 125 142 117 103 114 61 151 174 0.00
Market Capitalization		 39 29 119 141 163 128 123 67 103 81 0.00
Book Value per Share		 $0.73 $0.10 ($0.22) ($0.05) $0.76 $0.38 $0.01 ($0.58) ($1.01) ($1.68) ($2.01)
Tangible Book Value per Share		 $0.73 $0.10 ($0.22) ($0.05) $0.76 $0.38 $0.01 ($0.58) ($1.01) ($1.68) ($2.01)
Total Capital		 25 12 1.19 6.90 46 24 32 -22 12 3.16 7.54
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 29 9.86 72 106 134
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 29 9.86 72 85 134
Net Debt		 -26 -15 -3.05 -8.25 -47 -27 -11 -8.73 46 91 116
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.81 -3.35 -2.20 -1.53 -2.09 -3.08 -6.86 -11 -14 -12 -6.31
Debt-free Net Working Capital (DFNWC)		 25 12 0.85 6.72 45 24 33 7.54 12 2.96 11
Net Working Capital (NWC)		 25 12 0.85 6.72 45 24 33 7.54 12 -18 11
Net Nonoperating Expense (NNE)		 5.97 6.40 4.86 4.38 3.89 7.05 9.40 12 14 17 17
Net Nonoperating Obligations (NNO)		 -26 -15 -2.99 -7.95 -47 -27 -11 -8.66 46 91 116
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.00 0.00 0.04 0.04 0.04 0.03 0.03 0.04 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 28.83M 34.06M 37.57M 45.55M 57.03M 57.16M 58.53M 59.39M 60.16M 62.31M 63.90M
Adjusted Diluted Earnings per Share		 ($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 28.83M 34.06M 37.57M 45.55M 57.03M 57.16M 58.53M 59.39M 60.16M 62.31M 63.90M
Adjusted Basic & Diluted Earnings per Share		 ($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 59.36M 59.44M 61.90M 63.18M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -15 -11 -9.52 -9.41 -16 -21 -27 -27 -30 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -1,353.92 -40.48 -154.46 -269.47 -61.43 -36.59 -13.79 -7.55 -3.22
NOPAT to Interest Expense		 0.00 0.00 -947.74 -28.34 -108.12 -188.63 -43.20 -25.99 -9.55 -5.36 -1.92
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,353.92 -40.48 -154.46 -269.47 -61.43 -36.59 -13.79 -7.55 -3.22
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -947.74 -28.34 -108.12 -188.63 -43.20 -25.99 -9.55 -5.36 -1.92
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Galectin Therapeutics

This table displays calculated financial ratios and metrics derived from Galectin Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 59,582,253.00 61,848,657.00 61,903,672.00 62,148,134.00 62,278,125.00 62,761,825.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00
DEI Adjusted Shares Outstanding		 59,582,253.00 61,848,657.00 61,903,672.00 62,148,134.00 62,278,125.00 62,761,825.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.24 -0.16 -0.19 -0.20 -0.18 -0.19 -0.15 -0.12 -0.13 -0.09 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -15.69% 10.95% 5.07% -31.09% -1.69% -11.96% 24.77% 48.86% 34.73% 65.63% 61.05%
EBIT Growth		 -15.68% 10.93% 5.35% -31.34% -1.70% -11.96% 24.67% 48.84% 34.79% 65.27% 60.94%
NOPAT Growth		 -12.85% 10.08% 6.71% -25.41% 1.09% -29.99% 18.15% 59.04% 53.70% 72.92% 48.37%
Net Income Growth		 -21.30% 5.99% 0.33% -35.74% -7.59% -19.71% 16.17% 39.20% 27.06% 54.04% 47.61%
EPS Growth		 -71.43% 11.11% 0.00% -33.33% 25.00% -18.75% 21.05% 40.00% 27.78% 57.89% 46.67%
Operating Cash Flow Growth		 8.51% 35.05% -12.16% 15.25% -11.80% -172.03% 36.48% 20.77% 58.51% 52.76% 49.72%
Free Cash Flow Firm Growth		 588.42% -231.25% -153.45% -105.97% -142.55% 67.43% 262.28% -2,705.61% 157.42% 62.01% -311.11%
Invested Capital Growth		 -383.41% 65.50% 28.34% -16.71% 11.48% 15.58% -102.23% 77.17% -25.69% 14.99% 90.14%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -13.10% 4.48% -14.13% -6.32% 12.27% -5.17% 23.31% 27.72% -11.96% 44.62% 13.09%
EBIT Q/Q Growth		 -13.40% 4.46% -14.02% -6.32% 12.19% -5.17% 23.29% 27.78% -11.92% 43.98% 13.74%
NOPAT Q/Q Growth		 -1.81% -4.31% -0.91% -17.03% 19.71% -37.08% 36.46% 41.43% 9.23% 19.84% -21.16%
Net Income Q/Q Growth		 -14.42% 4.13% -14.92% -7.68% 9.30% -6.66% 19.52% 21.91% -8.82% 32.80% 8.25%
EPS Q/Q Growth		 -60.00% 33.33% -18.75% -5.26% 10.00% -5.56% 21.05% 20.00% -8.33% 38.46% 0.00%
Operating Cash Flow Q/Q Growth		 22.33% 38.43% -157.44% 31.16% -2.46% -49.81% 39.89% 14.14% 46.35% -70.58% 36.01%
Free Cash Flow Firm Q/Q Growth		 12.82% -229.10% 28.61% 94.26% -704.42% 1.18% 455.70% -199.23% 116.46% -165.38% -1,876.49%
Invested Capital Q/Q Growth		 -4.24% 65.42% -207.28% -5.35% 20.94% 67.02% -636.08% 88.11% -335.36% 77.69% 14.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 108.01% 108.38% 109.24% 110.63% 114.27% 115.88% 121.57% 131.46% 127.82% 153.33% 163.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 113.93% 88.85% 72.15% 66.46% 62.89% 57.62% 49.29% 40.48% 34.53% 26.90% 21.65%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 120.88% 93.14% 74.98% 68.68% 64.84% 59.19% 50.49% 41.38% 35.24% 27.42% 22.05%
Return on Equity Simple (ROE_SIMPLE)		 79.29% 0.00% 56.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.42 -6.69 -6.75 -7.90 -6.35 -8.70 -5.53 -3.24 -2.94 -2.36 -2.85
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 33.41% 17.63% 94.99% 18.41% 14.66% 4.76% 15.65% 5.98% 7.79% 3.03% 3.00%
Return On Investment Capital (ROIC_SIMPLE)		 - -68.45% 31.43% 36.22% 59.07% -607.09% 6.75% -206.47% 8.27% -40.49% -76.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.66 -9.22 -11 -11 -9.82 -10 -7.92 -5.72 -6.40 -3.59 -3.09
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.65 -9.22 -11 -11 -9.81 -10 -7.91 -5.72 -6.40 -3.55 -3.08
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 25.72 0.00 0.00 0.00 0.00 0.00 6.58 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.60 -1.19 -0.72 -0.76 -0.90 -1.03 -0.29 -1.03 -0.73 -1.06 -1.04
Long-Term Debt to Equity		 -0.60 -1.19 -0.72 -0.76 -0.79 -0.83 -0.10 -1.03 0.00 -1.06 -1.04
Financial Leverage		 -0.33 -0.41 -0.09 -0.36 -0.46 -0.84 -0.29 -0.72 -0.62 -0.90 -0.60
Leverage Ratio		 -0.55 -0.54 -0.41 -0.36 -0.36 -0.28 -0.19 -0.22 -0.19 -0.16 -0.10
Compound Leverage Factor		 -0.59 -0.58 -0.44 -0.40 -0.41 -0.32 -0.23 -0.29 -0.25 -0.25 -0.17
Debt to Total Capital		 -149.39% 623.83% -259.71% -308.67% -925.17% 3,365.84% -40.03% 3,660.22% -265.34% 1,773.67% 2,479.63%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% -116.59% 669.11% -26.54% 0.00% -265.34% 0.00% 0.00%
Long-Term Debt to Total Capital		 -149.39% 623.83% -259.71% -308.67% -808.58% 2,696.74% -13.49% 3,660.22% 0.00% 1,773.67% 2,479.63%
Preferred Equity to Total Capital		 -2.50% 4.35% -2.53% -2.49% -5.54% 15.84% -0.62% 14.89% -1.45% 6.50% 8.77%
Noncontrolling Interests to Total Capital		 -8.45% 14.98% -8.72% -8.57% -19.10% 54.59% -2.15% 52.35% -5.09% 22.85% 31.48%
Common Equity to Total Capital		 260.34% -543.17% 370.96% 419.73% 1,049.82% -3,336.28% 142.80% -3,627.47% 371.88% -1,703.02% -2,419.88%
Debt to EBITDA		 -0.77 -1.86 -1.35 -1.53 -2.05 -2.54 -0.82 -3.57 -2.96 -5.67 -7.24
Net Debt to EBITDA		 -0.26 -1.20 -0.73 -0.90 -1.39 -2.18 -0.63 -3.16 -2.58 -4.92 -6.49
Long-Term Debt to EBITDA		 -0.77 -1.86 -1.35 -1.53 -1.79 -2.04 -0.28 -3.57 0.00 -5.67 -7.24
Debt to NOPAT		 -1.11 -2.69 -1.96 -2.23 -3.01 -3.58 -1.13 -5.06 -4.40 -9.51 -11.92
Net Debt to NOPAT		 -0.37 -1.73 -1.06 -1.31 -2.04 -3.07 -0.87 -4.48 -3.83 -8.25 -10.68
Long-Term Debt to NOPAT		 -1.11 -2.69 -1.96 -2.23 -2.63 -2.87 -0.38 -5.06 0.00 -9.51 -11.92
Altman Z-Score		 -21.65 -17.46 -19.62 -19.17 -18.95 -34.93 -75.57 -37.83 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 -6.10% -4.82% -3.92% -3.34% -3.11% -2.72% -2.42% -2.23% -2.05% -1.93% -1.83%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.05 1.77 2.02 1.87 1.13 0.49 0.08 1.43 0.09 2.42 2.15
Quick Ratio		 1.94 1.64 1.86 1.75 1.07 0.43 0.07 1.28 0.08 2.21 1.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 26 -33 -24 -1.37 -11 -11 39 -38 6.33 -4.14 -82
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 31.03 -39.50 -22.70 -1.08 -7.38 -6.32 22.22 -21.06 3.48 -2.13 -41.16
Operating Cash Flow to Interest Expense		 -9.15 -5.55 -11.51 -6.57 -5.71 -7.42 -4.41 -3.62 -1.95 -3.12 -1.94
Operating Cash Flow Less CapEx to Interest Expense		 -9.15 -5.55 -11.51 -6.57 -5.71 -7.42 -4.41 -3.62 -1.95 -3.12 -1.94
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -41 -14 -43 -46 -36 -12 -88 -10 -45 -10 -8.64
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -32 27 17 -6.53 4.68 2.20 -44 35 -9.27 1.78 79
Enterprise Value (EV)		 127 151 178 179 230 174 104 242 0.00 0.00 0.00
Market Capitalization		 114 103 148 140 171 81 77 133 0.00 0.00 0.00
Book Value per Share		 ($0.89) ($1.01) ($1.18) ($1.36) ($1.52) ($1.68) ($1.82) ($1.88) ($1.96) ($2.01) ($2.01)
Tangible Book Value per Share		 ($0.89) ($1.01) ($1.18) ($1.36) ($1.52) ($1.68) ($1.82) ($1.88) ($1.96) ($2.01) ($2.01)
Total Capital		 -20 12 -20 -20 -9.02 3.16 -80 3.29 -34 7.54 5.47
Total Debt		 30 72 51 62 83 106 32 120 90 134 136
Total Long-Term Debt		 30 72 51 62 73 85 11 120 0.00 134 136
Net Debt		 10 46 28 36 56 91 25 107 78 116 122
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.27 -14 -11 -13 -13 -12 -88 -9.12 -45 -6.31 -5.73
Debt-free Net Working Capital (DFNWC)		 11 12 13 13 14 2.96 -80 4.65 -34 11 8.38
Net Working Capital (NWC)		 11 12 13 13 3.41 -18 -102 4.65 -124 11 8.38
Net Nonoperating Expense (NNE)		 4.01 3.30 4.74 4.47 4.87 3.27 4.10 4.28 5.25 3.14 2.19
Net Nonoperating Obligations (NNO)		 10 46 28 37 56 91 25 107 78 116 122
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.04 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.16) ($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 59.70M 60.16M 61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M
Adjusted Diluted Earnings per Share		 ($0.24) ($0.16) ($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 59.70M 60.16M 61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.85M 61.90M 62.15M 62.28M 62.76M 63.18M 0.00 0.00 0.00 0.00 65.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.42 -6.69 -6.75 -7.90 -6.35 -8.70 -5.53 -3.24 -2.94 -2.36 -2.85
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -11.56 -10.89 -10.00 -8.81 -6.57 -5.99 -4.54 -3.13 -3.52 -1.85 -1.56
NOPAT to Interest Expense		 -7.68 -7.90 -6.42 -6.23 -4.25 -5.04 -3.17 -1.77 -1.61 -1.21 -1.44
EBIT Less CapEx to Interest Expense		 -11.56 -10.89 -10.00 -8.81 -6.57 -5.99 -4.54 -3.13 -3.52 -1.85 -1.56
NOPAT Less CapEx to Interest Expense		 -7.68 -7.90 -6.42 -6.23 -4.25 -5.04 -3.17 -1.77 -1.61 -1.21 -1.44
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Galectin Therapeutics (NASDAQ: GALT) is still a pre-revenue biotech with heavy losses, but its latest quarter shows a mixed picture: cash remains adequate for now, while debt and accumulated deficits remain very large.

  • Cash and equivalents rose to $14.1 million at March 31, 2026, up from $11.5 million at Sept. 30, 2025 and $7.4 million at March 31, 2025.
  • Operating cash burn improved in Q1 2026, with cash used in operations of $3.9 million versus $6.0 million in Q4 2025 and $7.7 million in Q1 2025.
  • R&D spending fell to $2.2 million in Q1 2026 from $2.9 million in Q4 2025 and $6.5 million in Q1 2025, which helped reduce quarterly losses.
  • Net loss narrowed to $5.0 million in Q1 2026 from $5.5 million in Q4 2025 and $9.6 million in Q1 2025.
  • Quarterly operating expenses also declined to $4.1 million from $4.2 million in Q3 2025 and $7.9 million in Q1 2025.
  • The company had no revenue in any of the periods provided, so results continue to depend on financing and development progress.
  • Q1 2026 financing included only $257,000 of debt issuance, a much smaller amount than the $10.0 million to $12.2 million raised in some prior quarters.
  • Weighted average shares outstanding were 65.8 million in Q1 2026, up from 63.9 million in Q4 2025 and 62.0 million in Q1 2025, pointing to continued dilution risk over time.
  • Total liabilities remain extremely high at $146.0 million, far above total assets of $15.8 million.
  • The balance sheet still shows a large negative equity position of $132.0 million, reflecting a highly leveraged and financially stressed capital structure.
  • Long-term debt stood at $135.7 million in Q1 2026, compared with only $10.8 million at the start of 2025, indicating a much heavier debt burden than a year ago.
  • Retained earnings worsened to negative $437.6 million, underscoring years of cumulative losses.

Bottom line: GALT’s latest quarter shows some improvement in spending and cash burn, but the company remains a high-risk biotech with no revenue, heavy debt, and deeply negative equity. For retail investors, the main story is still financing risk and dependence on future clinical or strategic catalysts rather than operating fundamentals.

07/11/26 01:40 PM ETAI Generated. May Contain Errors.

Galectin Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Galectin Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Galectin Therapeutics' net income appears to be on an upward trend, with a most recent value of -$30.84 million in 2025, rising from -$20.03 million in 2015. The previous period was -$47.05 million in 2024. View Galectin Therapeutics' forecast to see where analysts expect Galectin Therapeutics to go next.

Galectin Therapeutics' total operating income in 2025 was -$20.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $20.09 million

Over the last 10 years, Galectin Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Galectin Therapeutics' total liabilities were at $145.73 million at the end of 2025, a 20.9% increase from 2024, and a 10,615.2% increase since 2015.

In the past 10 years, Galectin Therapeutics' cash and equivalents has ranged from $3.05 million in 2017 to $47.48 million in 2019, and is currently $17.72 million as of their latest financial filing in 2025.

Over the last 10 years, Galectin Therapeutics' book value per share changed from 0.73 in 2015 to -2.01 in 2025, a change of -375.0%.


Related Companies

Financial statements for NASDAQ:GALT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel